000140376 001__ 140376
000140376 005__ 20240826135844.0
000140376 0247_ $$2doi$$a10.1212/WNL.0000000000006318
000140376 0247_ $$2pmid$$apmid:30209235
000140376 0247_ $$2ISSN$$a0028-3878
000140376 0247_ $$2ISSN$$a1526-632X
000140376 0247_ $$2altmetric$$aaltmetric:48498238
000140376 037__ $$aDZNE-2020-06698
000140376 041__ $$aEnglish
000140376 082__ $$a610
000140376 1001_ $$aSteinacker, Petra$$b0
000140376 245__ $$aSerum neurofilament light chain in behavioral variant frontotemporal dementia.
000140376 260__ $$a[S.l.]$$bOvid$$c2018
000140376 264_1 $$2Crossref$$3online$$bOvid Technologies (Wolters Kluwer Health)$$c2018-09-12
000140376 264_1 $$2Crossref$$3print$$bOvid Technologies (Wolters Kluwer Health)$$c2018-10-09
000140376 3367_ $$2DRIVER$$aarticle
000140376 3367_ $$2DataCite$$aOutput Types/Journal article
000140376 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1724673498_30327
000140376 3367_ $$2BibTeX$$aARTICLE
000140376 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140376 3367_ $$00$$2EndNote$$aJournal Article
000140376 520__ $$aObjective: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).Methods: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration–related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry.Results: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p = 0.0006, respectively). At baseline and follow-up, NfL correlated with functional scores of patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r = −0.5857, p < 0.0001; 95% confidence interval −0.7415 to −0.3701). For patients with AD/MCI, NfL correlated with the functional performance as well (e.g., CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r = 0.5659, p = 0.0003) but not with regional brain volumes.Conclusions: As serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure for clinical trials.Classification of evidence: This study provides Class III evidence that for patients with cognitive problems, serum NfL concentration discriminates bvFTD from other forms of dementia.
000140376 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000140376 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x1
000140376 588__ $$aDataset connected to CrossRef, PubMed,
000140376 650_7 $$2NLM Chemicals$$aBiomarkers
000140376 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000140376 650_7 $$2NLM Chemicals$$aneurofilament protein L
000140376 650_2 $$2MeSH$$aAged
000140376 650_2 $$2MeSH$$aAlzheimer Disease: blood
000140376 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000140376 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000140376 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000140376 650_2 $$2MeSH$$aAtrophy
000140376 650_2 $$2MeSH$$aBiomarkers: blood
000140376 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000140376 650_2 $$2MeSH$$aBrain: pathology
000140376 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000140376 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000140376 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000140376 650_2 $$2MeSH$$aCognitive Dysfunction: genetics
000140376 650_2 $$2MeSH$$aDiagnosis, Differential
000140376 650_2 $$2MeSH$$aDisease Progression
000140376 650_2 $$2MeSH$$aFemale
000140376 650_2 $$2MeSH$$aFollow-Up Studies
000140376 650_2 $$2MeSH$$aFrontotemporal Dementia: blood
000140376 650_2 $$2MeSH$$aFrontotemporal Dementia: diagnostic imaging
000140376 650_2 $$2MeSH$$aFrontotemporal Dementia: genetics
000140376 650_2 $$2MeSH$$aFrontotemporal Dementia: pathology
000140376 650_2 $$2MeSH$$aHumans
000140376 650_2 $$2MeSH$$aMale
000140376 650_2 $$2MeSH$$aMiddle Aged
000140376 650_2 $$2MeSH$$aMutation
000140376 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000140376 650_2 $$2MeSH$$aOrgan Size
000140376 650_2 $$2MeSH$$aProspective Studies
000140376 7001_ $$aAnderl-Straub, Sarah$$b1
000140376 7001_ $$0P:(DE-HGF)0$$aDiehl-Schmid, Janine$$b2
000140376 7001_ $$aSemler, Elisa$$b3
000140376 7001_ $$aUttner, Ingo$$b4
000140376 7001_ $$avon Arnim, Christine A F$$b5
000140376 7001_ $$aBarthel, Henryk$$b6
000140376 7001_ $$0P:(DE-HGF)0$$aDanek, Adrian$$b7
000140376 7001_ $$aFassbender, Klaus$$b8
000140376 7001_ $$0P:(DE-HGF)0$$aFliessbach, Klaus$$b9
000140376 7001_ $$aFoerstl, Hans$$b10
000140376 7001_ $$aGrimmer, Timo$$b11
000140376 7001_ $$aHuppertz, Hans-Jürgen$$b12
000140376 7001_ $$aJahn, Holger$$b13
000140376 7001_ $$aKassubek, Jan$$b14
000140376 7001_ $$aKornhuber, Johannes$$b15
000140376 7001_ $$aLandwehrmeyer, Bernhard$$b16
000140376 7001_ $$aLauer, Martin$$b17
000140376 7001_ $$aMaler, Juan Manuel$$b18
000140376 7001_ $$aMayer, Benjamin$$b19
000140376 7001_ $$aOeckl, Patrick$$b20
000140376 7001_ $$0P:(DE-2719)2380559$$aPrudlo, Johannes$$b21
000140376 7001_ $$0P:(DE-2719)2812035$$aSchneider, Anja$$b22$$udzne
000140376 7001_ $$aVolk, Alexander E$$b23
000140376 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b24
000140376 7001_ $$aSchroeter, Matthias L$$b25
000140376 7001_ $$0P:(DE-HGF)0$$aLudolph, Albert C$$b26
000140376 7001_ $$0P:(DE-HGF)0$$aOtto, Markus$$b27$$eCorresponding author
000140376 7001_ $$agroup, FTLDc study$$b28
000140376 7001_ $$aAlbrecht, Franziska$$b29
000140376 7001_ $$aBisenius, Sandrine$$b30
000140376 7001_ $$aFeneberg, Emily$$b31
000140376 7001_ $$aHaefner, Sibylle$$b32
000140376 7001_ $$0P:(DE-HGF)0$$aKasper, Elisabeth$$b33
000140376 7001_ $$0P:(DE-HGF)0$$aKurzwelly, Delia$$b34
000140376 7001_ $$aLampe, Leonie$$b35
000140376 7001_ $$0P:(DE-HGF)0$$aLevin, Johannes$$b36
000140376 7001_ $$aLornsen, Finn$$b37
000140376 7001_ $$aLuley, Maxine$$b38
000140376 7001_ $$aOberstein, Timo$$b39
000140376 7001_ $$aPellkofer, Hannah$$b40
000140376 7001_ $$aPrix, Catharina$$b41
000140376 7001_ $$aRichter-Schmidinger, Tanja$$b42
000140376 7001_ $$aRoth, Nina$$b43
000140376 7001_ $$aSabri, Osama$$b44
000140376 7001_ $$aSchachner, Lisa$$b45
000140376 7001_ $$aSchomburg, Robert$$b46
000140376 7001_ $$aSchönecker, Sonja$$b47
000140376 7001_ $$aSchuemberg, Katharina$$b48
000140376 7001_ $$0P:(DE-HGF)0$$aSpottke, Annika$$b49
000140376 7001_ $$0P:(DE-HGF)0$$aTeipel, Stefan$$b50
000140376 7001_ $$0P:(DE-HGF)0$$aWilken, Petra$$b51
000140376 7001_ $$aZech, Heike$$b52
000140376 77318 $$2Crossref$$3journal-article$$a10.1212/wnl.0000000000006318$$b : Ovid Technologies (Wolters Kluwer Health), 2018-09-12$$n15$$pe1390-e1401$$tNeurology$$v91$$x0028-3878$$y2018
000140376 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000006318$$gVol. 91, no. 15, p. e1390 - e1401$$n15$$pe1390-e1401$$q91:15<e1390 - e1401$$tNeurology$$v91$$x0028-3878$$y2018
000140376 909CO $$ooai:pub.dzne.de:140376$$pVDB
000140376 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2380559$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b21$$kDZNE
000140376 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812035$$aExternal Institute$$b22$$kExtern
000140376 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000140376 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000140376 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x1
000140376 9141_ $$y2018
000140376 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2022-11-12$$wger
000140376 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2021$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000140376 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEUROLOGY : 2021$$d2022-11-12
000140376 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000140376 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x1
000140376 980__ $$ajournal
000140376 980__ $$aVDB
000140376 980__ $$aI:(DE-2719)1510100
000140376 980__ $$aI:(DE-2719)1410006
000140376 980__ $$aUNRESTRICTED